Keyword Tag Sort by

Endocrine therapy News (1 article)

Novartis drug Afinitor® met primary endpoint of Phase III study in women with advanced breast cancer; potential to address significant unmet need

Trial stopped early after positive interim results showed everolimus plus exemestane extended time without tumor growth Postmenopausal ER+HER2- metastatic breast cancer patients whose disease has progressed despite initial endocrine therapy need effective new...

Published on 5 July 2011, 14:27